Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Weight Loss Drug Mounjaro to Be Launched in India in 2025; Know How It Tackles Obesity
Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
Soap Central on MSN8h
What is Mounjaro prescribed for? Elon Musk seemingly reveals taking weight loss drug in his Christmas post
In the past, the Tesla CEO voiced his support for weight-loss drugs like Ozempic in an effort to tackle the nation's rising ...
2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.
Alaska Dispatch News16hOpinion
Opinion: We’ve accepted Wegovy and Zepbound. The next phase is harder.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Benefits Pro3h
Medicaid spending on GLP-1s exceeded $3.5B in past year
California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.